|
| Press Releases |
|
 |
|
| Thursday, October 6, 2022 |
|
|
中国疫苗行业的主要参与者艾美疫苗于香港联合交易所主板挂牌 |
| 按2021年批签发量计(不包括COVID-19疫苗)，中国第二大疫苗公司艾美疫苗股份有限公司(“艾美疫苗”或“公司”，连同其附属公司，统称“集团”，股份代号：06660.HK)今天成功登陆香港联合交易所有限公司主板，正式挂牌进行买卖，每手买卖单位为 200 H股。 more info >> |
|
|
中國疫苗行業的主要參與者艾美疫苗於香港聯合交易所主板掛牌 |
| 按2021年批簽發量計(不包括COVID-19疫苗)，中國第二大疫苗公司艾美疫苗股份有限公司(「艾美疫苗」或「公司」，連同其附屬公司，統稱「集團」，股份代號：06660.HK)今天成功登陸香港聯合交易所有限公司主板，正式掛牌進行買賣，每手買賣單位為 200 H股。 more info >> |
|
|
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK |
| AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. more info >> |
|
| Wednesday, October 5, 2022 |
|
|
艾美疫苗公布全球发售结果 每股H股发售股份发售价为16.16港元 |
| 按2021年批签发量计(不包括COVID-19疫苗)，中国第二大疫苗公司艾美疫苗股份有限公司（「艾美疫苗」或「公司」，连同其附属公司，统称「集团」，股份代号：06660.HK），今天宣布全球发售结果，每股发售股份定价为16.16港元 more info >> |
|
|
艾美疫苗公佈全球發售結果 每股H股發售股份發售價為16.16港元 |
| 按2021年批簽發量計(不包括COVID-19疫苗)，中國第二大疫苗公司艾美疫苗股份有限公司（「艾美疫苗」或「公司」，連同其附屬公司，統稱「集團」，股份代號：06660.HK），今天宣佈全球發售結果，每股發售股份定價為16.16港元 more info >> |
|
|
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share |
| AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines) more info >> |
|
| Friday, September 23, 2022 |
|
|
艾美疫苗宣布于港交所主板上市计划 |
| 按2021年批签发量计(不包括COVID-19疫苗)，中国第二大疫苗公司艾美疫苗股份有限公司(“艾美疫苗”或“公司”，连同其附属公司，统称“集团”，股份代号：06660.HK)今天宣布于香港联合交易所有限公司(“联交所”)主板上市计划。 more info >> |
|
|
艾美疫苗宣佈於港交所主板上市計劃 |
| 按2021年批簽發量計(不包括COVID-19疫苗)，中國第二大疫苗公司艾美疫苗股份有限公司(「艾美疫苗」或「公司」，連同其附屬公司，統稱「集團」，股份代號：06660.HK)今天宣佈於香港聯合交易所有限公司(「聯交所」)主板上市計劃。 more info >> |
|
|
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK |
| AIM Vaccine Co., Ltd. ("AIM Vaccine"; 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today. more info >> |
|
| Wednesday, January 12, 2022 |
|
|
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance |
| On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of the phase I clinical trial data of its mRNA COVID-19 vaccine (LVRNA009). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Daeshin MC Co., Ltd. 推出清潔解決方案 從工業現場到公共設施營造宜人的室內環境
Nov 24, 2024 08:00 HKT/SGT
|
|
|
Daeshin MC Co., Ltd.推出清洁解决方案 从工业现场到公共设施营造宜人的室内环境
Nov 24, 2024 08:00 HKT/SGT
|
|
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
